An alternative model for drug development: The story of fexinidazole
Nathalie Strub-Wourgaft, NTD Director, DNDi, Geneva

Working in partnership for sleeping sickness elimination: Using new technologies
Florent Mbo, HAT Platform Coordinator, DRC (presenting on behalf of Eric Mwamba Miaka, Director National HAT Programme, DRC)

Finding every last case: The role of diagnostics in HAT elimination
Veerle Lejon, Research Director, Institut de Recherche pour le Développement (IRD), France

Importance of the development of an oral treatment for sleeping sickness through public-private partnership
Luc Kuykens, Senior Vice President Global Health Programs, Sanofi, France

Differing responses to CD immunoassays: T. cruzi genetic diversity vs. host immune response
Claudia Herrera, Tulane University, New Orleans, USA

Latest developments in biomarkers research
Eric Chatelain, Head of Drug Discovery Programme, DNDi, Switzerland

Community-Based screening of Chagas disease in the USA: Boston’s Strong Hearts Program
Julia Koehler, Boston Children’s Hospital, Boston, USA

Implementation of a simplified diagnostic algorithm in an endemic area of Colombia
Colin Forsyth, Chagas Epidemiologist, DNDi North America

The burden of skin disease and eye disease due to onchocerciasis in Africa for 1990, 2015 and 2025
Vinkeles Melchers NVS, Stolk WA, Remme JHF, Murdoch ME, Pedrique B, Bakker R, de Vlas SJ, Coffeng LE 

Novel 3-Dimensional Optical Scanning in the assessment of patients with mycetoma
Siddig E, Liberton N, van Eijnatten M, te Slaa S, Faroog A, Fahal AH, Wolff J, Zijlstra EE

Pharmacokinetic-pharmacodynamic assessment of the safety of fexinidazole for the treatment of human African trypanosomiasis
Watson J, Strub-Wourgraft N, Tarral A, Tarning J, White NJ

Modeling and simulations of fexinidazole treatment regiment for human African trypanosomia brucei gambiense trypanosomiasis (g-HAT) and their successful clinical application in adult and child patients
Gualano V, Felices M, Tarral A

Oxfendazole treatment has a macrofilaricidal efficacy against the filarial nematode Litomosoides sigmodontisin vivo and inhibits Onchocerca gutturosa adult worm motility in vitro
Hübner MP, Martin C, Specht S, Koschel M, Dubben B, Frohberger SJ, Ehrens A, Fendler M, Struever D, Vallarino-Lhermitte N, Gokooi S, Townson S, Hoerauf A, Scandale I

The Chagas disease study landscape: preliminary results of a systematic review of clinical and observational studies to assess the feasibility of establishing an individual participant-level data (IPD) platform
Maguire BJ, Guérin PJ, Chatelain E, Sosa Estani S, Barreira F

A single-center, first-in-human, randomized, double-blind, placebo-controlled, parallel-group study to investigate the safety, tolerability and pharmacokinetics of escalating single doses of emodepside (BAY44-4400) in healthy male subjects
Gillon JYA, van den Berg F, Dequatre Cheeseman K, Hopchet N, Delhomme S, Peña Rossi C, Monnot F, Strub-Wourgaft N, Rodriguez ML, Don R.

Capacity Building Platform for clinical and operational research on human African trypanosomiasis
Mbo F, Valverde O

Prioritizing pathogens to support diagnostic product development for febrile illness management: a novel yet pragmatic approach
Roddy P, Osborn J, Roberts T, Guillen E, Bernal O, Ongarello S, Sprecher A, Page AL, Ribeiro I, Piriou E, Tamrat A, de la Tour R, Rao B, Flevaud L, Jensen T, McIver L, Kelly C, Dittrich S

Evaluation of point-of-care tests for visceral leishmaniasis diagnosis in Kenya
Mbuchi M, Ndung’u JM, Wasunna M, Osuna F, Magiri CG, Muia A, Kioko P, Bakari M, Mwathe F, Ronoh R, Abner E, Chirchir M, Njenga S, Kirigi G, Kimutai R, Cruz I

Sequential versus classical designs for early phase drug trials against visceral leishmaniasis
Alexander ND, Alves F, Balasegaram M, Blesson S, Burza S, Edwards T, Omollo R, Wasunna M